Skip to main content
. 2016 Nov;101(11):1426–1433. doi: 10.3324/haematol.2016.145847

Figure 3.

Figure 3.

Overall survival for low, intermediate and high biomarker risk panel groups in myeloablative (MA) conditioning cohort (A) and reduced intensity/non-myeloablative regimen cohorts (NMA) (B). Transplant-related mortality for low, intermediate and high biomarker risk panel groups in MA conditioning cohort (C) and reduced intensity/NMA regimen cohorts (D).